一种改进的小鼠局灶性脑缺血神经症状定量评价方法

本文旨在建立一种客观评价小鼠局灶性脑缺血神经症状的定量方法。在大脑中动脉阻塞诱导局灶性脑缺血后24h,采用悬挂试验分别测定转动的平均角和优势角以及转动次数,并用爬板试验测定小鼠攀爬角度;分析定量测定指标与脑梗死体积、神经元密度的相关性,并与经典的行为学评价方法比较。还以此法观察抗脑缺血药{pranlukast,4-氧-8-[对-(4-苯丁氧基)苯甲酰氨基]-2-(5-四氮基)-4H-1-苯并吡喃半水化合物}(ONO-1078)的作用。结果显示,脑缺血小鼠各项指标均有显著改变,定量评价总分与脑梗死体积、神经元密度减少密切相关,与经典行为学评分之间也密切相关。ONO-1078可显著抑制缺血损伤,并降低定量评价总分。因此,本方法可反映局灶性脑缺血神经症状变化,具有客观、定量、操作简便、无损伤的优点,并能用于评价抗脑缺血药物的作用。     

吸氧预处理对大鼠脑缺血再灌注损伤的保护作用

目的探讨吸氧预处理对大鼠脑缺血再灌注损伤的保护作用。方法通过大鼠局灶脑缺血再灌注损伤模型,采用SOD、MDA测定、电镜及神经行为学检查的方法,观察吸氧预处理对大鼠脑缺血再灌注损伤后SOD、MDA、神经行为学评分及脑组织病理变化。结果吸氧预处理组SOD活力高于对照组(P<0.05),MDA含量、神经行为学评分均低于对照组(P<0.05),脑组织超微结构损伤均减轻。结论吸氧预处理对大鼠脑缺血再灌注损伤有保护作用。     

线栓法制备不同体重KM小鼠局灶性脑缺血/再灌注模型的建立及评价

目的线栓法制备小鼠脑缺血/再灌注模型,并探讨影响该模型稳定性的因素。方法 KM小鼠100只,雌雄各半,体重20～39 g,分别将雌雄KM小鼠随机分为假手术组(n=20)和不同体重实验组(n=80)。其中实验组按小鼠体重分为以下8组:A组(♂,20～24 g)、B组(♂,25～29 g)、C组(♂,30～34 g)、D组(♂,35～39g),E组(♀,20～24 g)、F组(♀,25～29 g)、G组(♀,30～34 g)、H组(♀,35～39 g),每组10只。线栓栓塞法制备局灶性脑缺血/再灌注模型,选用单丝尼龙线(直径0.128～0.180 mm),液体石蜡处理浸泡后,从右侧颈总动脉进线,阻塞大脑中动脉血流,再灌注时拔出线栓,并对模型进行评价,采用的主要观察指标是神经功能损伤评分和2,3,5-三苯基氯化四氮唑(TTC)染色。结果同假手术相比,不同体重实验组小鼠脑缺血再灌注后,出现神经行为功能异常,TTC染色脑组织显示出明显的梗塞灶。与C、D组相比,A、B两组行为学评分以及梗死灶体积显著性增加(P<0.01);与G、H组相比,E、F两组的行为学评分以及梗死灶体积也显著性增加(P<0.01,P<0.05)。雄性KM小鼠与雌性相比,成模率较高且死亡率相对较低。此外,A组与E组相比,其行为学评分显著增加(P<0.01);B组与F组相比,小鼠行为学评分以及脑梗塞体积显著增加(P<0.01)。结论体重在25 g左右的雄性KM小鼠制备模型成功率较高,死亡率较低,适合建立小鼠局灶性脑缺血/再灌注模型。     

双丹胶囊对大鼠脑缺血再灌注损伤保护作用研究

目的：观察双丹胶囊对大鼠局灶性脑缺血再灌注损伤的脑梗死体积、自由基变化的影响,探讨双丹胶囊对脑缺血损伤的保护作用。方法：复制大鼠中动脉缺血再灌注模型,分别给药干预,在给药后观察行为学、脑梗死率、脑指数、脑含水量、SOD、MAD等指标。结果：双丹胶囊可改善动物的神经行为学评分,明显降低动物的脑梗死率、脑指数、脑含水量、提高脑组织SOD活性、降低MDA含量,并成剂量依赖。结论：双丹胶囊对脑缺血再灌注损伤具有保护作用。     

上肢精准测试系统在食蟹猴脑缺血研究中的应用

目的使用上肢精准测试系统对脊髓间充质干细胞治疗脑缺血的疗效进行行为学分析评价。方法成年食蟹猴18只,手术前2个月用上肢精准测试系统对动物进行训练并采集本底数据。采用光化学法制作局部脑缺血模型,造模后4周将动物随机分为对照组、干细胞治疗高剂量组和低剂量组,分别在缺血灶周围注射生理盐水、脊髓间充质干细胞5×106/只和1×106/只,造模后1 d、3 d、1、2、3、4周及干细胞注射后1d、3 d、1、2、3、4、5、6、8周采集行为学实验数据。比较造模前后和干细胞注射前后动物受损伤侧上肢抓取水果块的时间,结合神经功能评分评价造模和干细胞治疗效果。结果 18只动物手术后均出现与梗死部位对应的行为学症状。在术后采集数据的各个时间点损伤侧上肢行为学数据与手术前差异均存在极显著性（P〈0.01）。神经功能评分术后24 h最高,随后出现渐进性恢复。干细胞治疗后3 d到治疗后第8周,模型组动物与高、低剂量组动物间精准上肢运动测试结果差异均存在显著性（P〈0.05）。神经功能评分在治疗2周后出现显著性差异（P〈0.05）。高、低剂量组间差异未见显著性。结论上肢精准测试系统能客观准确的反应动物神经功能,在非人灵长类脑卒中动物模型建立和药效学评价方面有广泛应用前景。     

缺血预适应对小鼠脑缺血再灌注损伤模型血脑屏障的保护作用及机制

目的:通过研究缺血预适应对小鼠脑缺血再灌注损伤血脑屏障通透性的影响,探讨缺血预适应的脑保护作用及相关分子机制。方法:取清洁健康成年小鼠72只,随机分为脑缺血预适应组(brain ischemic precondition,BIP),脑缺血再灌注组(middle cerebral artery occlusion and reperfusion,MCAO/R)和假手术组(sham group),每组均24只,采用zealonga线栓法栓塞小鼠大脑中动脉建立BIP模型和MCAO/R模型,通过氯化三苯基四氮唑(triphenyl tetrazolium chloride,TTC)染色计算脑梗死面积,改良神经功能缺损评分(modified neurological severity scores,m NSS)对脑缺血再灌注神经损伤程度进行评估,测干-湿重法以及伊文氏蓝(Evans blue,EB)示踪结合脑组织EB定量法评价血脑屏障(blood brain barrier,BBB)的损伤程度,采用免疫组化法检测各组脑组织低氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)的表达。结果:与MCAO组相比,BIP组显著降低缺血再灌注后m NSS评分,缩小了梗死面积并减轻脑水肿,有效的保护BBB功能,BIP组再灌注24 h时脑梗死灶周围皮质区HIF-1α及VEGF的表达均明显上调,差异有统计学意义(P0.05)。结论:BIP对小鼠脑缺血再灌注损伤模型BBB有一定的保护作用,其机制可能与其诱导HIF-1α及VEGF的表达上调有关。     

小鼠脑缺血再灌注模型稳定性研究

目的:探讨影响小鼠脑缺血再灌注模型成功率,梗死体积以及行为学评分稳定性的因素。方法:采用昆明小鼠75只,体重为20-23 g,随机分为5组,比较在不同长度的线栓以及不同进栓深度的条件下对小鼠脑缺血再灌注模型成功率,梗死体积以及行为学评分的稳定性的影响。同时术中行脑血流监测,比较各组小鼠大脑中动脉脑血流下降的差异。结果:规格1组,模型成功率为40%,梗死体积为(16.7±9.3)%,神经功能缺损评分(NSS):7.2±2.4,大脑中动脉(MCA)血流下降百分比:(86.9±4.2)%;规格2组,模型成功率为46.7%,梗死体积百分比为(19.2±11.6)%,NSS:8.8±2.5,MCA血流下降百分比:(87.4±3.8)%;规格3组,模型成功率为33.3%,梗死体积百分比为(16.6±9.6)%,NSS:8.2±2.6,MCA血流下降百分比:(88.3±3.4)%;规格4组,模型成功率为86.7%,梗死体积百分比为(23.4±2.2)%,NSS:13.9±1.3,MCA血流下降百分比:(87.5±3.5)%。结论:1.小鼠脑缺血再灌注模型稳定性关键因素在于线栓能对后交通动脉(PComA)和大脑前动脉(ACA)起始段形成有效栓塞。2.小鼠大脑中动脉血流监测并不能作为评价小鼠脑缺血再管注模型成功与否的主要依据。     

丹参酮ⅡA与丹皮酚配伍对大鼠脑缺血再灌注损伤保护作用研究

目的：研究丹参酮ⅡA与丹皮酚配伍（简称双丹配伍）对大鼠局灶性脑缺血再灌注损伤的脑梗死体积、自由基变化的影响,探讨双丹配伍对脑缺血损伤的保护作用。方法：复制大鼠中动脉缺血再灌注模型,分别给予双丹配伍干预,观察和评价受试动物行为学、脑梗死率、脑指数、脑含水量、SOD、MAD等指标的变化。结果：①双丹配伍的各试药组均具有明显改善局灶性脑缺血再灌注损伤大鼠的神经行为学评分,降低脑梗死率、脑指数、脑含水量、提高脑组织SOD活性、降低MDA含量;②双丹配伍各组中1：3配伍组的总体药效作用优于1：2和1：4组,但数据未见统计学差异;⑧双丹配伍尾静脉注射的药效作用明显优于预先灌胃组。结论：双丹配伍脂质体给大鼠口服和注射对脑缺血再灌注损伤具有显著保护作用。     

丹参酮Ⅱ A与丹皮酚配伍对大鼠脑缺血再灌注损伤保护作用研究

研究丹参酮ⅡA与丹皮酚配伍(简称双丹配伍)对大鼠局灶性脑缺血再灌注损伤的脑梗死体积、自由基变化的影响,探讨双丹配伍对脑缺血损伤的保护作用.方法:复制大鼠中动脉缺血再灌注模型,分别给予双丹配伍干预,观察和评价受试动物行为学、脑梗死率、脑指数、脑含水量、SOD、MAD等指标的变化.结果:①双丹配伍的各试药组均具有明显改善局灶性脑缺血再灌注损伤大鼠的神经行为学评分,降低脑梗死率、脑指数、脑含水量、提高脑组织SOD活性、降低MDA含量;②双丹配伍各组中1∶3配伍组的总体药效作用优于1∶2和1∶4组,但数据未见统计学差异;③双丹配伍尾静脉注射的药效作用明显优于预先灌胃组.结论:双丹配伍脂质体给大鼠口服和注射对脑缺血再灌注损伤具有显著保护作用.     

星形胶质细胞糖原动员改善大脑缺血再灌注损伤的研究

摘要 目的：探讨星形胶质细胞糖原动员是否对大脑缺血再灌注损伤有神经保护作用。方法：研究构建了星形胶质细胞特异性糖原分解代谢关键酶糖原磷酸化酶（Glycogen phosphorylase, GP）过表达转基因小鼠（GFAP-GP）,并通过免疫荧光染色对GP的含量进行验证。在小鼠大脑中动脉梗死/再通模型中,利用GFAP-GP小鼠促进再灌注后累积糖原的分解（糖原动员）,通过三苯基氯化四氮唑（Triphenyl tetrazolium chloride, TTC）染色分析再灌注后GFAP-GP小鼠的脑梗死面积,Corner test和Grid-walking test检测再灌注后GFAP-GP小鼠的神经行为学功能。结果：GFAP-GP小鼠中GP的含量发生了明显的增加,再灌注后GFAP-GP小鼠与野生型小鼠相比,脑糖原含量明显降低,梗死明显减少,肢体感觉与运动功能明显改善。结论：星形胶质细胞糖原动员可改善大脑缺血再灌注损伤。     

局部脑缺血－再灌注大鼠行为和运动功能的动态观察

采用定量的方法动态观察局部脑缺血－再灌注大鼠的行为和运动能力,旨在为缺血性脑损伤行为评价提供敏感的指标。用直径０．２ｍｍ的尼龙线经颈内动脉可逆性插入到大脑前动脉,建立局部脑缺血－再灌注大鼠模型。术后１、２、４、８、２４、４８ｈ观察神经症状。运动能力的评价采用握－引测验、网屏测验和转棒测验,在术后１、２、３、７、１４ｄ进行。主要结果如下：该模型的偏瘫很快消失,术后４ｈ就难以用肉眼观察出运动的异常。而提尾悬空试验的阳性体征持续到术后３ｄ,转棒的成绩在术后１周恢复正常。握－引和网屏测验未能显示出肌力的异常,应考虑设计更完善的方法以排除干扰因素。上述结果提示提尾悬空和转棒测验是评价脑缺血大鼠运动缺陷的简便、客观且较敏感方法。     

Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia

Olaparib was the first poly(ADP-ribose)polymerase inhibitor approved by Food and Drug Administration for oncology treatment. However, its neuroprotective effects have not been elucidated. This study aimed to evaluate the effects of olaparib in transient cerebral ischemia. A mouse model of transient middle cerebral artery occlusion was used. Reperfusion was performed at 2 h after ischemia. Different doses of olaparib (1, 3, 5, 10 and 25 mg/kg) were administered intraperitoneally immediately after reperfusion. Twenty-four hours after ischemia, the neurological score was assessed, and grip and string tests were performed to evaluate the behavioral deficits in the mice. Cresyl violet staining was used to assess cerebral edema and the lesion volume. Immunohistochemistry was performed to evaluate the expression of blood–brain barrier proteins collagen IV and claudin-5, as well as extravasation of IgG. Ischemia induced a neurological deficit, which was significantly ameliorated by olaparib at 3 and 5 mg/kg. However, this neuroprotective effect was not observed in mice treated with either low-dose or high-dose olaparib. Both 3 and 5 mg/kg olaparib markedly reduced cerebral infarction volume, but not cerebral edema. The expression of collagen IV decreased after cerebral ischemia, which was improved by olaparib at 3 and 5 mg/kg. These results were confirmed by the reduction of IgG extravasation with olaparib. Olaparib showed clear neuroprotective effects in transient ischemic mice mainly through the reduction of cerebral infarction and blood–brain barrier damage.     

Acetyl-l-carnitine attenuates neuronal damage in gerbils with transient forebrain ischeia only when givenBefore the insult

The underlying mechanisms leading to neuronal damage in cerebral ischemia are multifactoral. In this study, we evaluated the neuroprotective effects of acetyl-l-carnitine, a medication that may enhance metabolic recovery after cerebral ischemia. The 5-minute transient forebrain ischemia model in gerbils was used. Acetyl-l-carnitine was given 30 minutes before the insult in one set of animals and 30 minutes after the insult in a second set of animals with histological evaluation at 7 days (Group A) and 28 days (Group B). Damage assessment was done using a 4-point damage score and Mann-Whitney U test was used for statistical analysis. Compared to the controls, there was significant protection in the cerebral cortex, hippocampus and the striatum in animals treated with the medicationbefore the insult in Group A and Group B Post-ischemic therapy showed little evidence of neuronal protection in either group. Behavioral tests in the Group B animals showed no significant differences between the treated or the saline controls. Our study shows, that pre-ischemic treatment with acetyl-l-carnitine results in neuronal protection. This may have clinical significance in situations (such as bypass surgery) where treatment could be initiatedprior to the insult.     

Antiischemic Effects of Topiramate in a Transient Global Forebrain Ischemia Model: A Neurochemical,Histological, and Behavioral Evaluation

The mechanisms of action of the anticonvulsant topiramate (TPM) are indicative of a potential benefit during cerebral ischemia. TPM was studied in a transient global forebrain ischemia (TGFI) model in gerbils in which 40 mg/kg was administered before or after TGFI. Control groups were administered 0.9% normal saline similarly. The evaluation consisted of neurochemical, histological, and functional analyses. The data obtained indicates that unlike the focal cerebral ischemia model, TPM is not neuroprotective in TGFI. The difference in effect, which may be due to the difference in species or the type of ischemia, points to the need for caution when extrapolating animal data from this drug to humans.     

Transgenic mouse brains for the evaluation and quality control of BSE tests

Rapid BSE tests are widely used diagnostics in veterinary medicine and more than 11 million tests are applied worldwide. The evaluation of new rapid BSE tests and the quality assurance of approved BSE tests pose a challenge owing to the natural scarcity of BSE-infected bovine brainstems and regional variations in prion titer. Transgenic mice expressing bovine prion protein (Tg4092) offer an alternative approach to these problems. To determine whether BSE-infected Tg4092 mouse brains could serve as a general standard for rapid BSE tests, we inoculated Tg4092 mice intracerebrally with BSE prions, harvested brains at defined time points post-infection and analyzed cerebral hemispheres with several approved rapid BSE tests. The results show that de novo formation of the disease-causing prion protein isoform, PrP(Sc), can be monitored during the course of infection. We demonstrate that BSE-infected Tg4092 mouse brains provide a renewable and controllable source of reference samples and suggest that such samples can generally be used for the evaluation and quality control of rapid BSE tests.     

消栓通胶囊抗脑缺血作用的实验研究

目的:观察消栓通胶囊对双侧颈总动脉结扎的大鼠脑缺血的保护作用;对小鼠断头后存活时间的影响.方法:采用结扎大鼠双侧颈总动脉以造成脑缺血模型,观察消栓通胶囊的药理作用.结果:①a.消栓通胶囊对双侧颈总动脉结扎大鼠脑含水量及脑指数有显著影响,消栓通胶囊三个剂量组(0.20 g/kg、0.40 g/kg、0.80 g/kg),脑含水量明显减少,与模型组有显著差异(P＜0.05或P＜0.01).b.组织病理学检查表明消栓通胶囊组的脑组织神经细胞浓缩及深染较脑缺血模型组明显减轻;神经胶质细胞肿胀及间质疏松程度均明显轻于模型组.②消栓通胶囊三个剂量组(0.20 g/kg、0.40 g/kg、0.80 g/kg)均能明显降低全血粘度值,与模型组比较有明显差异(P＜0.05或P＜0.01);③消栓通胶囊三个剂量组(025g/kg、0.50g/kg、1.00 g/kg)给药14d,与正常组比较可延长小鼠断头喘气的时间(P＜0.05或P＜0.01).结论:消栓通胶囊对大鼠结扎双侧颈总动脉所致脑缺血损伤具有明显的保护作用.     

Repetitive intraperitoneal caspase-3 inhibitor and anesthesia reduces neuronal damage

Caspase inhibitors are usually administered intracranially. There’s very limited evidence showing that they can be used intraperitoneally, and still have a beneficial effect. We tested the hypothesis that, during focal cerebral ischemia, caspase inhibitors when used in combination with an anesthetic agent results in a significantly reduction in the neuronal damage. Male Sprague Dawley rats were randomly divided into six different groups: control, Isoflurane, Propofol, Isoflurane and Caspase-3 inhibitor intraperitoneally (IP), propofol and Caspase-3 inhibitor IP and only caspase-3 inhibitor, during post-ischemia. Neurological evaluation and histochemical analysis was assessed post-ischemia. The treatment proposed, resulted in a significant decrease in the cerebral infarction volume. Combination of treatments, and caspase-3 inhibitor alone significantly decreased the number of TUNEL and cleaved caspase-3 positive cells in the boundary area of cortical infarction. IP administration appears to reach cerebral targets similarly to intracerebral model. This combination reduces the neurological damage caused by focal cerebral ischemia.     

A Type-II Positive Allosteric Modulator of α7 nAChRs Reduces Brain Injury and Improves Neurological Function after Focal Cerebral Ischemia in Rats

In the absence of clinically-efficacious therapies for ischemic stroke there is a critical need for development of new therapeutic concepts and approaches for prevention of brain injury secondary to cerebral ischemia. This study tests the hypothesis that administration of PNU-120596, a type-II positive allosteric modulator (PAM-II) of α7 nicotinic acetylcholine receptors (nAChRs), as long as 6 hours after the onset of focal cerebral ischemia significantly reduces brain injury and neurological deficits in an animal model of ischemic stroke. Focal cerebral ischemia was induced by a transient (90 min) middle cerebral artery occlusion (MCAO). Animals were then subdivided into two groups and injected intravenously (i.v.) 6 hours post-MCAO with either 1 mg/kg PNU-120596 (treated group) or vehicle only (untreated group). Measurements of cerebral infarct volumes and neurological behavioral tests were performed 24 hrs post-MCAO. PNU-120596 significantly reduced cerebral infarct volume and improved neurological function as evidenced by the results of Bederson, rolling cylinder and ladder rung walking tests. These results forecast a high therapeutic potential for PAMs-II as effective recruiters and activators of endogenous α7 nAChR-dependent cholinergic pathways to reduce brain injury and improve neurological function after cerebral ischemic stroke.     

多因素复合制作气虚血瘀证脑缺血动物模型的实验研究

目的通过复制气虚血瘀证型大鼠脑缺血动物模型,探索病证结合动物模型制作方法.方法选用老年Wistar大鼠,采用饥饿、疲劳、寒湿、惊恐、高脂饮食等多因素复合方法复制气虚血瘀证动物模型,采用双侧颈总动脉结扎复制脑缺血动物模型.结果通过对一般体征和微观指标的观测,发现模型大鼠基本符合中医气虚血瘀证候特点和现代医学脑缺血病理变化规律.[HTH〗结论多因素复合作用可成功复制病证结合动物模型,本动物模型有可能成为将来中医药防治脑缺血科研工作的实验基础.     

阻断趋化因子CXCL10对脑缺血再灌注损伤及神经炎症的影响

目的:探讨趋化因子CXCL10在脑缺血再灌注损伤中对神经炎症的影响。方法:(1)线栓法建立脑缺血再灌注损伤大鼠模型,TTC染色检测梗死面积,Western blot检测CXCL10的表达;(2)建立小鼠神经瘤母细胞N2a氧糖剥夺/复氧(oxygen-glucose deprivation/reoxygenation,OGD/R)模型,通过CXCR3拮抗剂-NBI 74330阻断趋化因子CXCL10表达,Western blot检测CXCL10和CXCR3蛋白的表达;Real-time PCR检测CXCL10、CXCR3以及神经炎症因子TNF-α、IL-1β、IL-2 m RNA的表达。结果:(1)脑缺血再灌注(cerebral ischemia reperfusion injury,CIRI)模型大鼠脑梗死侧CXCR10的表达量显著高于其对侧和假手术组(P<0.05);(2)阻断CXCL10使得小鼠神经瘤母细胞N2a中CXCL10、CXCR3以及炎症因子TNF-α、IL-1β、IL-2的表达量均显著降低(P<0.05);(3)阻断CXCL10使得小鼠神经瘤母细胞细胞凋亡率降低(P<0.05)。结论:抑制CXCL10降低了氧糖剥夺模型细胞炎症因子的表达,表明阻断CXCL10可能通过减轻神经炎症在脑缺血再灌注损伤中发挥保护作用。